Hualan Biological Vaccine Inc. (SHE:301207)
14.05
-0.15 (-1.06%)
Nov 17, 2026, 3:04 PM CST
Hualan Biological Vaccine Revenue
Hualan Biological Vaccine had revenue of 256.50M CNY in the quarter ending September 30, 2026, a decrease of -65.62%. This brings the company's total for the last twelve months to 697.41M, down -28.58% year-over-year. In the year 2025, Hualan Biological Vaccine had annual revenue of 1.20B with 6.62% growth. That makes Hualan Biological Vaccine the 22,366th largest company in the world by revenue and 4,082nd in China.
Revenue (ttm)
697.41M
Revenue Growth
-28.58%
P/S Ratio
11.99
Revenue / Employee
985.04K
Employees
708
Market Cap
8.36B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Hualan Biological Vaccine breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20B | 74.69M | 6.62% |
| Dec 31, 2024 | 1.13B | -1.28B | -53.21% |
| Dec 31, 2023 | 2.41B | 584.79M | 32.03% |
| Jan 1, 2023 | 1.83B | -4.17M | -0.23% |
| Jan 1, 2022 | 1.83B | -596.52M | -24.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.74B |
| Pacific Shuanglin Bio-pharmacy | 2.42B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.16B |
| Shanghai Medicilon | 1.54B |
| Vcanbio Cell & Gene Engineering Corp., | 1.38B |
| Liaoning Chengda Biotechnology | 1.34B |
| Shanghai OPM Biosciences | 822.13M |
| Chongqing Genrix Biopharmaceutical | 800.98M |